Background Metformin exhibited an antitumor effect in several preclinical and clinical studies. The results of phase III studies have been generally discouraging. The aim of the current study was to investigate if metformin use enhances pathological response to neoadjuvant therapy in breast cancer (BC) cases. The primary outcome was the tumor response rate.